We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

By LabMedica International staff writers
Posted on 25 Apr 2025

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. More...

Deubiquitinating (DUB) enzymes contain around 100 proteins that remove ubiquitin from a variety of substrates. Widely involved in the regulation of cellular processes including cell proliferation, autophagy, DNA damage repair, and immune response – DUBs have been implicated in a range of human diseases and consequently are attractive targets for potential therapeutic intervention via the development of suitable inhibitors and modulators. Now, a new range of DUB enzyme assay kits can accelerate routine DUB activity assays without compromising data quality.

AMS Biotechnology (Amsbio, Abingdon, England) has launched a new range of DUB enzyme assay kits supplied in a convenient and easy-to-use 96-well assay format. These ready-to-use kits require minimal setup and no need for substrate preparation. The new kits are based on ubiquitin derivatives conjugated with various fluorophores that enable sensitive and specific detection using a microplate reader at an excitation wavelength of 485 nm and an emission wavelength of 535 nm. The range includes kits tailored to individual DUB enzymes such as BAP1, USP7, and UCHL1, enabling researchers to precisely profile activity or screen inhibitors against disease-relevant targets.

Designed to quickly measure deubiquitinase activity or inhibitor screening in purified enzyme systems and cell-based models – these new assay kits come optimized for both kinetic and endpoint analysis. Supplied in an industry standard 96-well microplate format these DUB enzyme assay kits are high throughput screening compatible and ready-to-use by academic, biotech and pharma researchers. The areas of research that may benefit from these kits include cancer tumor suppression and cell cycle regulation; neurodegenerative diseases, such as Parkinson’s, via mitochondrial and protein clearance pathways and immune system function and inflammation, where DUBs regulate cytokine signaling and innate immunity.

Related Links:
Amsbio


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.